Evaluating iCare COMPASS as a Visual Field Diagnostic Tool

August 11, 2026 updated by: Masood Mohammadi, Indiana University
this study seeks to compare the Humphrey Visual Field Analyzer and iCare COMPASS for both clinical accuracy and operational advantages.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

28

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • Indiana
      • Indianapolis, Indiana, United States, 46202
        • Eugene and Marilyn Glick Eye Institute

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • All consenting patients who arrive for glaucoma management appointments for objective(s) 2.1.1, 2.2.2
  • Patient groups arriving for glaucoma management that will be targeted for enrollment include: glaucoma suspect patients, those with cataracts, optic atrophy, macular degeneration, macular pathology, and vascular diseases of the retina

Exclusion Criteria:

  • Those who are unwilling or unable to provide consent
  • Those for which English is not their first language

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Diagnostic
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: HUMPHREY SITA FASTER VS ICARE COMPASS
SUBJECTS WILL BE RANDOMIZED TO TESTING ON THE HUMPHREY SITA FASTER VISUAL FIELD FIRST, THEN WILL TEST ON THE ICARE COMPASS VISUAL FIELD MACHINE
Diagnostic test: VISUAL FIELD TESTING
This study will be a crossover study. Patients who express interest in taking part in the study will be evaluated using Humphrey SITA-faster, which is the current standard of care for visual perimetry, and the iCare COMPASS in the same visit. Participants will be assigned to one of two groups of alternating testing order with the Humphrey Visual Field Analyzer vs the iCare COMPASS and vice versa. The mean deviation, pattern standard deviation, mean deviation cluster, and fixation plot results will be compared. For analysis, participants will be grouped according to the inclusion criteria.
Active Comparator: ICARE COMPASS VS HUMPHREY SITA FASTER
SUBJECTS WILL BE RANDOMIZED TO TEST FIRST ON THE ICARE COMPASS VISUAL FIELD MACHINE, THEN WILL TEST ON THE HUMPHREY SITA FASTER VISUAL FIELD MACHINE
Diagnostic test: VISUAL FIELD TESTING
This study will be a crossover study. Patients who express interest in taking part in the study will be evaluated using Humphrey SITA-faster, which is the current standard of care for visual perimetry, and the iCare COMPASS in the same visit. Participants will be assigned to one of two groups of alternating testing order with the Humphrey Visual Field Analyzer vs the iCare COMPASS and vice versa. The mean deviation, pattern standard deviation, mean deviation cluster, and fixation plot results will be compared. For analysis, participants will be grouped according to the inclusion criteria.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Visual Fields will be assessed via the current standard of care Humphrey SITA-Faster when available. The mean deviation, pattern standard deviation, mean deviation cluster, and fixation plot obtained will be compared with the same measures on the iCare
Time Frame: within 1-3 months post visit
Testing will be performed with either one or two encounters with the patient or as determined by the patients' clinician.
within 1-3 months post visit

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Indiana University

Investigators

  • Principal Investigator: MASOOD MOHAMMADI, MD, Indiana University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 7, 2025

Primary Completion (Actual)

January 16, 2026

Study Completion (Actual)

January 16, 2026

Study Registration Dates

First Submitted

August 11, 2026

First Submitted That Met QC Criteria

August 11, 2026

First Posted (Actual)

August 14, 2026

Study Record Updates

Last Update Posted (Actual)

August 14, 2026

Last Update Submitted That Met QC Criteria

August 11, 2026

Last Verified

August 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 22747

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

Yes

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe